Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.

Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ.

Cancer Treat Rev. 2013 Dec;39(8):891-907. doi: 10.1016/j.ctrv.2013.05.007. Epub 2013 Jun 21. Review.

PMID:
23790634
2.

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.

Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, Belldegrun A, Cloughesy TF.

Neurosurg Focus. 2000 Dec 15;9(6):e8.

PMID:
16817691
3.

Clinical trials with immunotherapy for high-grade glioma.

Ruzevick J, Jackson C, Phallen J, Lim M.

Neurosurg Clin N Am. 2012 Jul;23(3):459-70. doi: 10.1016/j.nec.2012.04.003. Epub 2012 Jun 8. Review.

PMID:
22748658
4.

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S.

J Neurooncol. 2010 Sep;99(2):261-72. doi: 10.1007/s11060-010-0131-y. Epub 2010 Feb 10.

PMID:
20146084
5.

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S.

Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.

PMID:
22527250
6.

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.

Cancer Res. 2004 Jul 15;64(14):4973-9.

7.

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.

De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW.

Clin Cancer Res. 2008 May 15;14(10):3098-104. doi: 10.1158/1078-0432.CCR-07-4875.

8.

Vaccine therapies for patients with glioblastoma.

Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT.

J Neurooncol. 2014 Sep;119(3):531-46. doi: 10.1007/s11060-014-1502-6. Epub 2014 Aug 28. Review.

PMID:
25163836
9.

DCVax-Brain and DC vaccines in the treatment of GBM.

Wheeler CJ, Black KL.

Expert Opin Investig Drugs. 2009 Apr;18(4):509-19. doi: 10.1517/13543780902841951 . Review.

PMID:
19335279
10.

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA.

Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. doi: 10.1007/s00262-013-1453-3. Epub 2013 Jul 2.

11.

Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA, Lewis LD, Ernstoff MS.

J Immunother. 2011 May;34(4):382-9. doi: 10.1097/CJI.0b013e318215e300.

12.

DCVax®-L--developed by Northwest Biotherapeutics.

Polyzoidis S, Ashkan K.

Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276. Review. Erratum in: Hum Vaccin Immunother. 2015;11(7):1881.

13.

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.

Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS.

Cancer Immunol Immunother. 2013 Jan;62(1):125-35. doi: 10.1007/s00262-012-1319-0. Epub 2012 Jul 31.

14.

Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.

Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB.

Cancer Invest. 2014 Nov;32(9):451-7. doi: 10.3109/07357907.2014.958234. Epub 2014 Sep 26. Review.

PMID:
25259676
15.

Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.

Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, Chen CC, Harn HJ, Liu CL, Lee WY, Ho LH.

World Neurosurg. 2012 May-Jun;77(5-6):736-44. doi: 10.1016/j.wneu.2011.08.020. Epub 2011 Nov 7.

PMID:
22120301
16.

Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.

Batich KA, Swartz AM, Sampson JH.

Expert Opin Biol Ther. 2015 Jan;15(1):79-94. doi: 10.1517/14712598.2015.972361. Epub 2014 Oct 18. Review.

PMID:
25327832
17.

Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.

Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW.

Clin Cancer Res. 2005 Jul 15;11(14):5292-9.

18.

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.

Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS.

Stem Cells. 2009 Aug;27(8):1734-40. doi: 10.1002/stem.102.

19.

Overview of cellular immunotherapy for patients with glioblastoma.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V.

Clin Dev Immunol. 2010;2010. pii: 689171. doi: 10.1155/2010/689171. Epub 2010 Oct 4. Review.

20.

Cellular-based immunotherapies for patients with glioblastoma multiforme.

Xu X, Stockhammer F, Schmitt M.

Clin Dev Immunol. 2012;2012:764213. doi: 10.1155/2012/764213. Epub 2012 Feb 28. Review.

Items per page

Supplemental Content

Write to the Help Desk